Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microtransplantation with Azacitidine for Elderly AML
NCT05262465Unknown
- Sponsor
- Shandong Guomei Industry
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of HLA-mismatched microtransplantation in acute myeloid leukemia (AML), sponsored by Shandong Guomei Industry. Primary endpoint: Remission Rate at 2 months. Status: unknown.
02
Drugs
HLA-mismatched microtransplantation
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05262465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262465.